| pubmed-article:17963805 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17963805 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17963805 | lifeskim:mentions | umls-concept:C0032749 | lld:lifeskim |
| pubmed-article:17963805 | lifeskim:mentions | umls-concept:C0205322 | lld:lifeskim |
| pubmed-article:17963805 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:17963805 | lifeskim:mentions | umls-concept:C0449445 | lld:lifeskim |
| pubmed-article:17963805 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:17963805 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17963805 | pubmed:dateCreated | 2007-12-6 | lld:pubmed |
| pubmed-article:17963805 | pubmed:abstractText | Post-kala-azar dermal leishmaniasis (PKDL) is a recognized dermatosis that follows successful treatment of visceral leishmaniasis in the Sudan. This randomized and double-blind study aimed to assess safety, immunogenicity and curative potentials of a novel immunochemotherapy regimen in patients with persistent PKDL. Following informed consent, 30 patients were randomized to receive alum-precipitated autoclaved Leishmania major (Alum/ALM) vaccine+Bacille Calmette-Guérin (BCG) and sodium stibogluconate (SSG) or vaccine diluent and SSG. The SSG+Alum/ALM+BCG proved safe with minimal local adverse events. In the SSG+vaccine group, 87% of the patients were cured by day 60 compared with 53% in the SSG alone group (SSG+vaccine efficacy=71%, 95% CI for risk ratio 0.7-1.16). On day 90 of follow-up there were two relapses in the SSG alone arm and none in the SSG+vaccine arm. Pre-treatment cytokines showed high IFN-gamma or high IFN-gamma/IL-10 levels and leishmanin skin test (LST) non-reactivity, while healing/clinical improvement were associated with LST reactivity and low IFN-gamma levels in both study groups (P=0.004). In conclusion, SSG+Alum/ALM+BCG is safe and immunogenic with significant healing potentials in persistent PKDL lesions. Immunochemotherapy probably augmented IFN-gamma production, which induced healing. Leishmanin skin reactivity is a good surrogate marker of cure in persistent PKDL lesions. | lld:pubmed |
| pubmed-article:17963805 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17963805 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17963805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17963805 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17963805 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:17963805 | pubmed:issn | 0035-9203 | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:KhalilEltahir... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:NoazinSassanS | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:MusaAhmed... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:ModabberFarro... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:El-HassanAhme... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:MahgoubFawzi... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:ElgawiSara... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:ElkadaruAbd... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:AboudMona... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:GhalibHashim... | lld:pubmed |
| pubmed-article:17963805 | pubmed:author | pubmed-author:Leishmaniasis... | lld:pubmed |
| pubmed-article:17963805 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17963805 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:17963805 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17963805 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17963805 | pubmed:pagination | 58-63 | lld:pubmed |
| pubmed-article:17963805 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:meshHeading | pubmed-meshheading:17963805... | lld:pubmed |
| pubmed-article:17963805 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17963805 | pubmed:articleTitle | Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. | lld:pubmed |
| pubmed-article:17963805 | pubmed:affiliation | Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan. | lld:pubmed |
| pubmed-article:17963805 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17963805 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17963805 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17963805 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17963805 | lld:pubmed |
